DI CESARE, Antonella et al. Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study. Dermatology Practical & Conceptual, [S. l.], v. 15, n. 4, p. 5733, 2025. DOI: 10.5826/dpc.1504a5733. Disponível em: https://mail.dpcj.org/index.php/dpc/article/view/5733.. Acesso em: 9 may. 2026.